Quercetin for Squamous Cell Cancer in Fanconi Anemia
Trial Summary
Will I have to stop taking my current medications?
The trial requires that patients stop taking digoxin unless they cannot do so for medical reasons. If you are on digoxin and cannot stop, you may not be eligible to participate.
What evidence supports the effectiveness of the drug Quercetin for treating squamous cell cancer in Fanconi Anemia?
Research indicates that Quercetin, a natural compound found in many plants, has potential anti-cancer properties, including the ability to inhibit tumor growth and regulate cell cycles. Although more research is needed, preliminary studies suggest it may help in reducing cancer cell proliferation.12345
Is quercetin safe for human use?
What makes quercetin unique as a treatment for squamous cell cancer in Fanconi Anemia?
Quercetin is unique because it is a natural compound with antioxidant and anti-inflammatory properties that can inhibit the growth of certain cancer cells. It works by blocking substances involved in cell proliferation and inflammation, and its effectiveness is enhanced when combined with ascorbic acid, which protects it from oxidative degradation.5891011
What is the purpose of this trial?
Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure, variable congenital abnormalities and a predisposition to malignancy, particularly acute myeloid leukemia (AML) and squamous cell carcinoma (SCC). Improved transplant outcomes are modifying the natural history of Fanconi Anemia. Improved transplant survival, no radiation exposure, and almost no GVHD increases the importance of addressing later SCC even further. The investigators hypothesize that quercetin will prevent or delay the development of SCC and associated complications, there by ameliorating or delaying the need for potentially lethal treatment with chemotherapy and/or radiation therapy for the same.Funding Source - FDA Office of Orphan Products Development (OOPD)
Research Team
Parinda A Mehta, MD
Principal Investigator
Cincinnati Children's Hosptial Medical Center
Eligibility Criteria
This trial is for individuals over 2 years old with Fanconi anemia (FA), who can take medication by mouth. It's not for those pregnant, breastfeeding, at risk of pregnancy without birth control, or have taken antioxidants like quercetin in the last month. People undergoing cancer treatments or with certain liver and kidney conditions, or on digoxin therapy that can't be stopped are also excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive oral quercetin to prevent or delay the development of squamous cell carcinoma
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Quercetin
Quercetin is already approved in United States for the following indications:
- Herbal Supplementation
- Nonbacterial Chronic Prostatitis
- Interstitial Cystitis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital Medical Center, Cincinnati
Lead Sponsor